Media

27, March, 2018

Toronto

Prince Edward Island drug plan now includes REMICADE® for the treatment of multiple autoimmune diseases

15, February, 2018

Toronto, Ontario

Health Canada Approves New Indication for ZYTIGA^® (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer

15, November, 2017

Toronto

Janssen Inc. Announces Health Canada Approval of TREMFYA™ (guselkumab) for the Treatment of Adult Moderate to Severe Plaque Psoriasis

31, October, 2017

Toronto

Janssen Inc. Announces IMBRUVICA® (ibrutinib) as the First Approved Treatment for Chronic Graft-Versus-Host Disease (cGVHD) Granted by Health Canada Priority Review

25, October, 2017

Toronto

Janssen Inc. Announces Health Innovation Partnership with Memorial University of Newfoundland

12, June, 2017

Toronto, Ontario

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS Program

27, April, 2017

Toronto, Ontario

Janssen Inc. Applauds Government of Ontario Decision to Increase Funding For Drug Budget

17, April, 2017

Toronto, Ontario

Janssen Inc. Receives Health Canada Approval of DARZALEX® (daratumumab) by Priority Review for Patients with Multiple Myeloma Who Have Had At Least One Prior Therapy

22, March, 2017

Toronto, Ontario

Janssen Inc. Welcomes Recognition of Health/Bio-Sciences Innovation in 2017 Federal Budget

13, December, 2016

Toronto, Ontario

Health Canada Approves STELARA® for the Treatment of Adults with Moderately to Severely Active Crohn’s Disease